The state of the fight:Sanofi and GSK’s vaccine candidate demonstrated 58% efficacy against symptomatic Covid-19 in Phase 3.
Hetero Pharma’s generic version of Merck’s molnupiravir reduced the risk of hospitalization by over 65%.
Britain and Japan pledged a combined $514 million to CEPI’s pandemic preparedness plan. AUTHORIZED VACCINES
The U.S. FDA lifted its clinical hold on Bharat Biotech’s Covaxin, clearing the way for the inactivated vaccine…